01:00 PM EDT, 05/02/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target to $350 from $374, 16.2x our 2026 EPS view, above Amgen's ( AMGN ) 10-year recent historical forward average, justified by its robust outlook. We keep our 2025 EPS at $20.88 and 2026 EPS at $21.61. AMGN delivered a robust performance in Q1 2025, with significant improvements across key financial metrics, in our view. Q1 sales grew 9% Y/Y to $8.1B, driven by an 11% Y/Y increase in product sales. Amgen's ( AMGN ) product portfolio demonstrated strength across multiple offerings, in our view. Notably, 14 products achieved double-digit sales growth, including key assets such as Repatha, Blincyto, and Tezspire. The successful launch of Imdelltra generated $81M in sales during Q1, with promising Phase 3 results, supporting its potential as a new standard of care in second-line SCLC. Looking ahead, AMGN provided a positive outlook for 2025, with its reiterated revenue guidance of $34.3B to $35.7B and adj. EPS guidance of $20.00 to $21.20. We pencil in $35.4B in sales for 2025, pointing to a solid 5.9% Y/Y growth.